300439.SZ
美康生物
SZSE · Healthcare · C 制造业 · CN
CNY 9.23
−1.18%Year over year
Reported trailing growth
- Revenue
- -5.7%
- EBITDA
- —
- EBIT
- -83.0%
- EPS
- -67.9%
- Free cash flow
- +355.8%
- Operating cash flow
- -25.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.8%
- EBITDA
- -21.3%
- EBIT
- -47.4%
- Net income
- -31.7%
- EPS
- -32.5%
- Free cash flow
- -34.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026